{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:52:17Z","timestamp":1783385537764,"version":"3.54.6"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Understanding the clinical characteristics and underlying mechanisms of simultaneous geographic atrophy (GA) and choroidal neovascularization (CNV)\/macular neovascularization (MNV) is necessary for the long-term management of late age-related macular degeneration (AMD) in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The authors reviewed the literature on the incidence, risk factors, and clinical characteristics of simultaneous GA and CNV\/MNV and developed consensus recommendations for the diagnosis, assessment, and management of simultaneous GA and CNV\/MNV in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The incidence rate of CNV\/MNV in eyes with GA is reported as 7.4% per patient-year or 13.8% in 4.1 years, while that of macular atrophy (MA) subsequent to CNV\/MNV is reported as 24.4% to 37% in 24 months. Recent studies using optical coherence tomography angiography (OCT-A) revealed the presence of subclinical CNV\/MNV in 11% to 16% of eyes with GA. Fundus autofluorescence is used to detect MA; optical coherence tomography (OCT) and OCT-A are useful for detecting MA, especially around the fovea, with OCT-A offering high sensitivity and specificity in the detection of both MA and CNV\/MNV. GA and CNV\/MNV share the genetic risk factors of <jats:italic>HTRA1<\/jats:italic>, complement factor H, complement factors 3 and 2, and <jats:italic>ARMS2<\/jats:italic>, and clinical risk factors of large drusen, cuticular drusen, intraretinal hyperreflective foci, and subretinal drusenoid deposits, suggesting that simultaneous GA and CNV\/MNV represents a continuum of AMD. Anti\u2013vascular endothelial growth factor therapy for CNV\/MNV is reported to have no impact on the speed or magnitude of MA development or enlargement. An association has been observed between CNV subtype and MA progression, with the latter being slower in the presence of type 1 CNV\/MNV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest there is a high probability of coexistence of GA and CNV\/MNV and that they should not be considered separately. Future clinical studies should assess the two conditions simultaneously using OCT and OCT-A.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Messages<\/jats:title>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>What is known<\/jats:italic>\n              <\/jats:bold>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Owing to differences in their clinical characteristics, geographic atrophy (GA) and choroidal neovascularization (CNV)\/macular neovascularization (MNV) have historically been regarded as two separate entities; however, several cases of coexistent GA and CNV\/MNV have been reported recently in the published literature.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n            <jats:p>\n              <jats:bold>\n                <jats:italic>What is new<\/jats:italic>\n              <\/jats:bold>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>The findings of this review confirm that GA and CNV\/MNV share common genetic risk factors and clinical characteristics, and suggest that these two entities are part of a continuum of late-stage age-related macular degeneration (AMD).<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>The potential for GA and CNV\/MNV to coexist should be considered in any discussion of the long-term management of late AMD; moreover, clinicians should assess for CNV\/MNV in patients with GA, and for GA in those with CNV\/MNV, using multimodal imaging.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00417-024-06721-5","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:51:29Z","timestamp":1744645889000},"page":"1197-1212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Simultaneous GA and CNV\/MNV: incidence, characteristics, and treatments"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8795-6536","authenticated-orcid":false,"given":"Keiko","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-044X","authenticated-orcid":false,"given":"Richard","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0536-2951","authenticated-orcid":false,"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-7512","authenticated-orcid":false,"given":"Figen","family":"\u015eermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3302-5754","authenticated-orcid":false,"given":"Cynthia X.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3358-3516","authenticated-orcid":false,"given":"Chui Ming Gemmy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-1150","authenticated-orcid":false,"given":"Miltiadis K.","family":"Tsilimbaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-0017","authenticated-orcid":false,"given":"Igor","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"6721_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris III","year":"2013","unstructured":"Ferris FL III, Wilkinson CP, Bird A et al (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120:844\u2013851. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.036","journal-title":"Ophthalmology"},{"key":"6721_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"6721_CR3","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG et al (2018) Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3. Ophthalmology 125:537\u2013548. https:\/\/doi.org\/10.1016\/j.ophtha.2017.09.028","journal-title":"Ophthalmology"},{"key":"6721_CR4","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.ophtha.2017.11.036","volume":"125","author":"U Chakravarthy","year":"2018","unstructured":"Chakravarthy U, Bailey CC, Johnston RL et al (2018) Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 125:842\u2013849. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.036","journal-title":"Ophthalmology"},{"key":"6721_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.oret.2020.10.008","volume":"5","author":"CK Hwang","year":"2021","unstructured":"Hwang CK, Agr\u00f3n E, Domalpally A et al (2021) Progression of geographic atrophy with subsequent exudative neovascular disease in age-related macular degeneration: AREDS2 Report 24. Ophthalmol Retina 5:108\u2013117. https:\/\/doi.org\/10.1016\/j.oret.2020.10.008","journal-title":"Ophthalmol Retina"},{"key":"6721_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajo.2017.07.009","volume":"182","author":"V Capuano","year":"2017","unstructured":"Capuano V, Miere A, Querques L et al (2017) Treatment-na\u00efve quiescent choroidal neovascularization in geographic atrophy secondary to nonexudative age-related macular degeneration. Am J Ophthalmol 182:45\u201355. https:\/\/doi.org\/10.1016\/j.ajo.2017.07.009","journal-title":"Am J Ophthalmol"},{"key":"6721_CR7","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/s41433-022-02231-y","volume":"37","author":"T Mathis","year":"2023","unstructured":"Mathis T, Holz FG, Sivaprasad S et al (2023) Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes. Eye 37:1758\u20131765. https:\/\/doi.org\/10.1038\/s41433-022-02231-y","journal-title":"Eye"},{"key":"6721_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/archopht.1997.01100150743009","volume":"115","author":"MG Maguire","year":"1997","unstructured":"Maguire MG, Bressler SB, Bresskr NM et al (1997) Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 115:741\u2013747. https:\/\/doi.org\/10.1001\/archopht.1997.01100150743009","journal-title":"Arch Ophthalmol"},{"key":"6721_CR9","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS et al (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292\u20132299. https:\/\/doi.org\/10.1016\/j.ophtha.2013.03.046","journal-title":"Ophthalmology"},{"key":"6721_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Tuomi LL, Ding B et al (2018) Macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 125:878\u2013886. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.026","journal-title":"Ophthalmology"},{"key":"6721_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ophtha.2019.09.030","volume":"127","author":"S Gune","year":"2020","unstructured":"Gune S, Abdelfattah NS, Karamat A et al (2020) Spectral-domain OCT\u2013based prevalence and progression of macular atrophy in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 127:523\u2013532. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.030","journal-title":"Ophthalmology"},{"key":"6721_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","volume":"126","author":"C Bailey","year":"2019","unstructured":"Bailey C, Scott LJ, Rogers CA et al (2019) Intralesional macular atrophy in anti\u2013vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial. Ophthalmology 126:75\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2018.07.013","journal-title":"Ophthalmology"},{"key":"6721_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2019.08.023","volume":"127","author":"MC Gillies","year":"2020","unstructured":"Gillies MC, Hunyor AP, Arnold JJ et al (2020) Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology 127:198\u2013210. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.023","journal-title":"Ophthalmology"},{"key":"6721_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/IAE.0000000000000827","volume":"36","author":"JF Arevalo","year":"2016","unstructured":"Arevalo JF, Lasave AF, Wu L et al (2016) Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group. Retina 36:859\u2013867. https:\/\/doi.org\/10.1097\/IAE.0000000000000827","journal-title":"Retina"},{"key":"6721_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","volume":"122","author":"E Tanaka","year":"2015","unstructured":"Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM (2015) Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology 122:153\u2013161. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.046","journal-title":"Ophthalmology"},{"key":"6721_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1097\/IAE.0000000000001766","volume":"38","author":"JG Christenbury","year":"2018","unstructured":"Christenbury JG, Phasukkijwatana N, Gilani F et al (2018) Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti-vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina 38:1276\u20131288. https:\/\/doi.org\/10.1097\/IAE.0000000000001766","journal-title":"Retina"},{"key":"6721_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","volume":"125","author":"E Daniel","year":"2018","unstructured":"Daniel E, Pan W, Ying GS et al (2018) Development and course of scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 125:1037\u20131046. https:\/\/doi.org\/10.1016\/j.ophtha.2018.01.004","journal-title":"Ophthalmology"},{"key":"6721_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ophtha.2016.01.033","volume":"123","author":"RB Bhisitkul","year":"2016","unstructured":"Bhisitkul RB, Desai S, Boyer DS et al (2016) Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology 123:1269\u20131277. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.033","journal-title":"Ophthalmology"},{"key":"6721_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-020-01766-6","volume":"21","author":"J Siedlecki","year":"2021","unstructured":"Siedlecki J, Koch C, Schworm B et al (2021) Enlargement rate of geographic atrophy before and after secondary CNV conversion with associated anti-VEGF treatment. BMC Ophthalmol 21:1\u20138. https:\/\/doi.org\/10.1186\/s12886-020-01766-6","journal-title":"BMC Ophthalmol"},{"key":"6721_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","volume":"123","author":"E Daniel","year":"2016","unstructured":"Daniel E, Shaffer J, Ying GS et al (2016) Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 123:609\u2013616. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.034","journal-title":"Ophthalmology"},{"key":"6721_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ophtha.2017.08.030","volume":"125","author":"JR de Oliveira Dias","year":"2018","unstructured":"de Oliveira Dias JR, Zhang Q, Garcia JMB et al (2018) Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography. Ophthalmology 125:255\u2013266. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.030","journal-title":"Ophthalmology"},{"key":"6721_CR22","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/s2214-109x(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/s2214-109x(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"6721_CR23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.ophtha.2020.04.019","volume":"127","author":"TH Rim","year":"2020","unstructured":"Rim TH, Kawasaki R, Tham YC et al (2020) Prevalence and pattern of geographic atrophy in Asia: the Asian Eye Epidemiology Consortium. Ophthalmology 127:1371\u20131381. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.019","journal-title":"Ophthalmology"},{"key":"6721_CR24","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","volume":"3","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Grewal DS, Teo KYC et al (2019) The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration. Ophthalmol Retina 3:1045\u20131055. https:\/\/doi.org\/10.1016\/j.oret.2019.06.002","journal-title":"Ophthalmol Retina"},{"key":"6721_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ophtha.2016.12.002","volume":"124","author":"FG Holz","year":"2017","unstructured":"Holz FG, Sadda SR, Staurenghi G et al (2017) Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus Meetings. Ophthalmology 124:464\u2013478. https:\/\/doi.org\/10.1016\/j.ophtha.2016.12.002","journal-title":"Ophthalmology"},{"key":"6721_CR26","first-page":"298","volume":"8","author":"N Massamba","year":"2019","unstructured":"Massamba N, Sellam A, Butel N et al (2019) Use of fundus autofluorescence combined with optical coherence tomography for diagnose of geographic atrophy in age-related macular degeneration. Med Hypothesis Discov Innov Ophthalmol 8:298\u2013305","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"6721_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/IAE.0b013e318285cbd2","volume":"33","author":"C Alexandre de Amorim Garcia Filho","year":"2013","unstructured":"Alexandre de Amorim Garcia Filho C, Yehoshua Z, Gregori G et al (2013) Spectral-domain optical coherence tomography imaging of drusenoid pigment epithelial detachments. Retina 33:1558\u20131566. https:\/\/doi.org\/10.1097\/IAE.0b013e318285cbd2","journal-title":"Retina"},{"key":"6721_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/opo.12592","volume":"38","author":"NB Quinn","year":"2018","unstructured":"Quinn NB, Chakravarthy U, Muldrew KA et al (2018) Confocal infrared imaging with optical coherence tomography provides superior detection of a number of common macular lesions compared to colour fundus photography. Ophthalmic Physiol Opt 38:574\u2013583. https:\/\/doi.org\/10.1111\/opo.12592","journal-title":"Ophthalmic Physiol Opt"},{"key":"6721_CR29","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1167\/iovs.17-22508","volume":"58","author":"E Corbelli","year":"2017","unstructured":"Corbelli E, Sacconi R, Rabiolo A et al (2017) Optical coherence tomography angiography in the evaluation of geographic atrophy area extension. Invest Ophthalmol Vis Sci 58:5201\u20135208. https:\/\/doi.org\/10.1167\/iovs.17-22508","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6721_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00417-020-04821-6","volume":"259","author":"F Corvi","year":"2021","unstructured":"Corvi F, Cozzi M, Invernizzi A et al (2021) Optical coherence tomography angiography for detection of macular neovascularization associated with atrophy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 259:291\u2013299. https:\/\/doi.org\/10.1007\/s00417-020-04821-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6721_CR31","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/IAE.0000000000001863","volume":"38","author":"PL Nesper","year":"2018","unstructured":"Nesper PL, Lutty GA, Fawzi AA (2018) Residual choroidal vessels in atrophy can masquerade as choroidal neovascularization on optical coherence tomography angiography: introducing a clinical and software approach. Retina 38:1289\u20131300. https:\/\/doi.org\/10.1097\/IAE.0000000000001863","journal-title":"Retina"},{"key":"6721_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1136\/bjophthalmol-2014-305005","volume":"98","author":"C Saade","year":"2014","unstructured":"Saade C, Ganti B, Marmor M et al (2014) Risk characteristics of the combined geographic atrophy and choroidal neovascularisation phenotype in age-related macular degeneration. Br J Ophthalmol 98:1729\u20131732. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305005","journal-title":"Br J Ophthalmol"},{"key":"6721_CR33","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1167\/iovs.15-18572","volume":"57","author":"NS Abdelfattah","year":"2016","unstructured":"Abdelfattah NS, Zhang H, Boyer DS et al (2016) Drusen volume as a predictor of disease progression in patients with late age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci 57:1839\u20131846. https:\/\/doi.org\/10.1167\/iovs.15-18572","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6721_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ophtha.2017.08.033","volume":"125","author":"C Balaratnasingam","year":"2018","unstructured":"Balaratnasingam C, Cherepanoff S, Dolz-Marco R et al (2018) Cuticular drusen: clinical phenotypes and natural history defined using multimodal imaging. Ophthalmology 125:100\u2013118. https:\/\/doi.org\/10.1016\/j.ophtha.2017.08.033","journal-title":"Ophthalmology"},{"key":"6721_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ophtha.2015.10.029","volume":"123","author":"RP Finger","year":"2016","unstructured":"Finger RP, Chong E, McGuinness MB et al (2016) Reticular pseudodrusen and their association with age-related macular degeneration: The Melbourne Collaborative Cohort Study. Ophthalmology 123:599\u2013608. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.029","journal-title":"Ophthalmology"},{"key":"6721_CR36","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.ophtha.2019.05.016","volume":"126","author":"M Nassisi","year":"2019","unstructured":"Nassisi M, Lei J, Abdelfattah NS et al (2019) OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR study. Ophthalmology 126:1667\u20131674. https:\/\/doi.org\/10.1016\/j.ophtha.2019.05.016","journal-title":"Ophthalmology"},{"key":"6721_CR37","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1038\/eye.2012.107","volume":"26","author":"S Grob","year":"2012","unstructured":"Grob S, Luo J, Hughes G et al (2012) Genetic analysis of simultaneous geographic atrophy and choroidal neovascularization. Eye (Lond) 26:1106\u20131113. https:\/\/doi.org\/10.1038\/eye.2012.107","journal-title":"Eye (Lond)"},{"key":"6721_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jamaophthalmol.2021.6072","volume":"140","author":"S Schmitz-Valckenberg","year":"2022","unstructured":"Schmitz-Valckenberg S, Fleckenstein M, Zouache MA et al (2022) Progression of age-related macular degeneration among individuals homozygous for risk alleles on chromosome 1 (CFH-CFHR5) or chromosome 10 (ARMS2\/HTRA1) or both. JAMA Ophthalmol 140:252\u2013260. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.6072","journal-title":"JAMA Ophthalmol"},{"key":"6721_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1590\/s0004-27492012000400011","volume":"75","author":"MH Amaro","year":"2012","unstructured":"Amaro MH, Roller AB (2012) Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy. Arq Bras Oftalmol 75:273\u2013276. https:\/\/doi.org\/10.1590\/s0004-27492012000400011","journal-title":"Arq Bras Oftalmol"},{"key":"6721_CR40","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","volume":"32","author":"SY Cohen","year":"2012","unstructured":"Cohen SY, Oubraham H, Uzzan J et al (2012) Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina 32:1480\u20131485. https:\/\/doi.org\/10.1097\/IAE.0b013e318240a516","journal-title":"Retina"},{"key":"6721_CR41","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.ophtha.2015.08.015","volume":"122","author":"GS Ying","year":"2015","unstructured":"Ying GS, Maguire MG, Daniel E et al (2015) Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 122:2523\u20132531e2521. https:\/\/doi.org\/10.1016\/j.ophtha.2015.08.015","journal-title":"Ophthalmology"},{"key":"6721_CR42","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/02713683.2020.1849730","volume":"46","author":"G Casalino","year":"2021","unstructured":"Casalino G, Arrigo A, Introini U et al (2021) Clinical course of treated choroidal neovascularization in eyes with pre-existing geographic atrophy: case series and reappraisal of the literature. Curr Eye Res 46:988\u2013994. https:\/\/doi.org\/10.1080\/02713683.2020.1849730","journal-title":"Curr Eye Res"},{"key":"6721_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.oret.2023.12.012","volume":"8","author":"RP Gale","year":"2024","unstructured":"Gale RP, Airody A, Sivaprasad S et al (2024) Improved structure and function in early-detected second-eye neovascular age-related macular degeneration: FASBAT\/early detection of neovascular age-related macular degeneration report 1. Ophthalmol Retina 8:545\u2013552. https:\/\/doi.org\/10.1016\/j.oret.2023.12.012","journal-title":"Ophthalmol Retina"},{"key":"6721_CR44","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ophtha.2020.03.031","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Abdelfattah NS, Lei J et al (2020) Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 127:1360\u20131370. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.031","journal-title":"Ophthalmology"},{"key":"6721_CR45","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","volume":"4","author":"M Pfau","year":"2020","unstructured":"Pfau M, M\u00f6ller PT, K\u00fcnzel SH et al (2020) Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmol Retina 4:238\u2013248. https:\/\/doi.org\/10.1016\/j.oret.2019.09.016","journal-title":"Ophthalmol Retina"},{"key":"6721_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ajo.2021.08.018","volume":"235","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Hershberger V, Eichenbaum D et al (2022) Inhibition of complement factor 3 in geographic atrophy with NGM621: phase 1 dose-escalation study results. Am J Ophthalmol 235:131\u2013142. https:\/\/doi.org\/10.1016\/j.ajo.2021.08.018","journal-title":"Am J Ophthalmol"},{"key":"6721_CR47","unstructured":"NGM Bio (2022) NGM Bio announces topline results from the CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration. https:\/\/ir.ngmbio.com\/node\/9586\/pdf. Accessed 9 Apr 2025"},{"key":"6721_CR48","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao DS, Grossi FV, El Mehdi D et al (2020) Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology 127:186\u2013195. https:\/\/doi.org\/10.1016\/j.ophtha.2019.07.011","journal-title":"Ophthalmology"},{"key":"6721_CR49","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.ophtha.2021.02.025","volume":"128","author":"CC Wykoff","year":"2021","unstructured":"Wykoff CC, Rosenfeld PJ, Waheed NK et al (2021) Characterizing new-onset exudation in the randomized phase 2 FILLY trial of complement inhibitor pegcetacoplan for geographic atrophy. Ophthalmology 128:1325\u20131336. https:\/\/doi.org\/10.1016\/j.ophtha.2021.02.025","journal-title":"Ophthalmology"},{"key":"6721_CR50","unstructured":"Chiang A, Bliss C, Ribeiro R (2023) Assessment of geographic atrophy (GA) lesion progression in the phase 3 OAKS and DERBY trials. Invest Ophthalmol Vis Sci 64:986"},{"key":"6721_CR51","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG et al (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402:1434\u20131448. https:\/\/doi.org\/10.1016\/S0140-6736(23)01520-9","journal-title":"Lancet"},{"key":"6721_CR52","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","volume":"37","author":"SS Patel","year":"2023","unstructured":"Patel SS, Lally DR, Hsu J et al (2023) Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye 37:3551\u20133557. https:\/\/doi.org\/10.1038\/s41433-023-02497-w","journal-title":"Eye"},{"key":"6721_CR53","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","volume":"402","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Patel SS, Staurenghi G et al (2023) Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet 402:1449\u20131458. https:\/\/doi.org\/10.1016\/S0140-6736(23)01583-0","journal-title":"Lancet"},{"key":"6721_CR54","doi-asserted-by":"publisher","first-page":"109254","DOI":"10.1016\/j.exer.2022.109254","volume":"225","author":"G Malek","year":"2022","unstructured":"Malek G, Campisi J, Kitazawa K et al (2022) Does senescence play a role in age-related macular degeneration? Exp Eye Res 225:109254. https:\/\/doi.org\/10.1016\/j.exer.2022.109254","journal-title":"Exp Eye Res"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06721-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06721-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T22:03:21Z","timestamp":1749506601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06721-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6721"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06721-5","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not report any studies involving human or animal participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Keiko Kataoka received personal fees from Bayer, Boehringer Ingelheim, Canon MedTech, Chugai, OMC, Otsuka, Novartis, Santen, and Senju. Richard Gale is a consultant for AbbVie, Allergan, Apellis, Bayer, Biogen, Boehringer Ingelheim, Notal, Novartis, Roche, and Santen, and has received research grants from Bayer, Novartis, and Roche. Xiaoxin Li is a consultant for Kanghong, Novartis, and Ocumension, and has received research grants from Bayer. Figen \u015eermet is a consultant for AbbVie, Bayer, Novartis, Roche, and Thea. Cynthia X. Qian is a consultant for AbbVie, Apellis, Bayer, Boehringer Ingelheim, Novartis, and Roche. Chui Ming Gemmy Cheung has received consultant fees, speaker fees, and grant funding from Avirmax, Bayer, Boehringer Ingelheim, Iveric, Janssen, Novartis, Roche, Topcon, and Zeiss. Miltiadis K. Tsilimbaris has received personal fees from AbbVie, Bayer Hellas, Mavrogenis, and Novartis Hellas, and has received grants from Alcon, Bayer, Johnson & Johnson, and Novartis. Igor Kozak is a consultant for Alcon, Alimera, Allergan, Bayer, Roche, and Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}